Evidence map›Paper›PMID 40468048›Full record

ArticleActa pharmacologica Sinica2025

An endoplasmic reticulum-targeting photodynamic AMPK agonist activates breast cancer immunotherapy through promoting immunogenic cell death and downregulation of PD-L1.

Ye-Yang Wu, Ke-Yang Zhang, Jia-Qi Huang, Jun-Mei Nie, Hong Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ye-Yang WuSchool of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, China.
Ke-Yang ZhangSchool of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, China.
Jia-Qi HuangSchool of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, China.
Jun-Mei NieSchool of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, China.
Hong ChengSchool of Biomedical Engineering & Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou, 510515, China. chengh@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most aggressive malignancies exhibit low immunogenicity, exacerbated by tumor immune evasion mechanisms that undermine immunotherapy efficacy. Studies indicate that AMP-activated protein kinase (AMPK) directly phosphorylates programmed cell death ligand 1 (PD-L1), promoting its degradation via the endoplasmic reticulum (ER)-associated pathway to restore and sustain cytotoxic T lymphocyte-mediated immunity. Here, we developed an ER-targeting photodynamic AMPK agonist (called PPFC) for breast cancer immunotherapy. PPFC comprised a chimeric peptide (PpIX-(PEG8-FFKDEL)

Indexed as

AMP-Activated Protein KinasesB7-H1 AntigenBreast NeoplasmsEndoplasmic ReticulumImmunogenic Cell DeathImmunotherapyPhotochemotherapyPhotosensitizing AgentsAnimalsCell Line, TumorDown-RegulationEndoplasmic Reticulum StressFemaleHumansMiceMice, Inbred BALB CAMP-Activated Protein KinasesB7-H1 AntigenCD274 protein, humanPhotosensitizing AgentsReactive Oxygen Speciesbreast cancerdrug deliveryendoplasmic reticulum targetingimmunologic cell deathPD-L1photodynamic therapy

Identifiers

PMID40468048
PMCPMC12552511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.